These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11682352)

  • 1. Delay of simple reaction time after levodopa intake.
    Müller T; Benz S; Börnke C
    Clin Neurophysiol; 2001 Nov; 112(11):2133-7. PubMed ID: 11682352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choice reaction time after levodopa challenge in parkinsonian patients.
    Müller T; Benz S; Przuntek H
    J Neurol Sci; 2000 Dec; 181(1-2):98-103. PubMed ID: 11099718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apomorphine delays simple reaction time in Parkinsonian patients.
    Müller T; Benz S; Przuntek H
    Parkinsonism Relat Disord; 2002 Jun; 8(5):357-60. PubMed ID: 15177065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients.
    Muller T; Benz S; Przuntek H
    Can J Neurol Sci; 2002 Feb; 29(1):73-7. PubMed ID: 11858540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of the dopaminergic response in Parkinson's disease.
    Müller T; Benz S
    Parkinsonism Relat Disord; 2002 Jan; 8(3):181-6. PubMed ID: 12039429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Idiopathic Parkinson's disease: practical hints for the treatment].
    Ludin HP
    Praxis (Bern 1994); 2005 Jul; 94(30-31):1147-50. PubMed ID: 16117469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa medication improves incidental sequence learning in Parkinson's disease.
    Beigi M; Wilkinson L; Gobet F; Parton A; Jahanshahi M
    Neuropsychologia; 2016 Dec; 93(Pt A):53-60. PubMed ID: 27686948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment.
    Müller T; Benz S; Börnke C; Przuntek H
    Acta Neurol Scand; 2004 May; 109(5):348-54. PubMed ID: 15080862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
    Dessibourg CA; Gachoud JP
    Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 12. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic substitution in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2002 Oct; 3(10):1393-403. PubMed ID: 12387685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson's disease.
    Müller T; Harati A
    J Neural Transm (Vienna); 2020 Feb; 127(2):265-272. PubMed ID: 32008089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of levodopa on the habituation of the acoustic-palpebral reflex in Parkinson's disease.
    Rey RD; Garretto NS; Bueri JA; Simonetti DD; Sanz OP; Sica RE
    Electromyogr Clin Neurophysiol; 1996 Sep; 36(6):357-60. PubMed ID: 8891475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reach-to-grasp movement in Parkinson's disease before and after dopaminergic medication.
    Castiello U; Bennett KM; Bonfiglioli C; Peppard RF
    Neuropsychologia; 2000; 38(1):46-59. PubMed ID: 10617291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS; Covicković-Sternić N
    Neurologija; 1990; 39(2):99-105. PubMed ID: 2267052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease.
    Zach H; Dirkx MF; Roth D; Pasman JW; Bloem BR; Helmich RC
    Neurology; 2020 Sep; 95(11):e1461-e1470. PubMed ID: 32651292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.